.@vitarnabio/ @artanbio partners with @Syenex to accelerate ARTAN-102 delivery using the VivoCell Platform! This collab combines:
> VitaRNA's codon suppressor tech targeting age-related mutations > Syenex's precision in vivo delivery expertise
The goal? Speed up the path from proof-of-concept to IND-enabling studies while staying capital-efficient 💊
Led by CSO Dr. Michael Torres ( @Mykalt45), the team's recent safety data shows ARTAN-102 reaches multiple tissues (liver, heart, lung, brain) with no adverse events in mice. 🐭
Next up: Non-human primate studies as they push toward human trials!